Update From the Field of Renal Sympathetic Denervation: A Focus on Safety Nomenclature Considerations J. Rick Turner Editorial 30 December 2017 Pages: 664 - 668
Editorial Board Member’s Commentary: Commissioner Scott Gottlieb’s Predictable Imaginarium Peter J. Pitts Editorial 30 December 2017 Pages: 669 - 670
Use of Qualitative Data to Support Content Validity of Performance-Based Cognitive Outcome Assessments Chris J. Edgar Letter to the Editor 30 December 2017 Pages: 671 - 671
Implications of CRISPR-Based Germline Engineering for Cancer Survivors Gregory KatzPeter J. Pitts Commentary 30 December 2017 Pages: 672 - 682
Reference Limits for Outlier Analyses in Randomized Clinical Trials Charles M. Beasley Jr.Brenda CrowePaul S. Horn Clinical Trials: Original Research 30 December 2017 Pages: 683 - 737
Dose Finding in Late-Phase Drug Development Lei NieKyung Y. LeeRajeshwari Sridhara Clinical Trials: Original Research 30 December 2017 Pages: 738 - 743
Optimized Medical Product Regulation in Mexico: A Win-Win for Public and Economic Health Mikel Andoni Arriola PeñalosaRicardo Cavazos CepedaMurray M. Lumpkin Global Perspectives: Original Research 30 December 2017 Pages: 744 - 750
The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review Raimond Lozda Global Perspectives: Review 30 December 2017 Pages: 751 - 755
Bone Mineral Density to Assess Pediatric Bone Health in Drug Development Brian M. MaasJian WangGilbert J. Burckart Product Development & Innovation: Original Research 30 December 2017 Pages: 756 - 760
Adaptive Seamless Design for Establishing Pharmacokinetic and Efficacy Equivalence in Developing Biosimilars Ryuji UozumiChikuma Hamada Product Development & Innovation: Original Research 30 December 2017 Pages: 761 - 769
Assessing Recall and Recognition for Important Safety Information in Digital Promotion for Pharmaceutical Products: Implications for Website Design Michael PolsterClifford ThummaNisith Kumar Product Safety: Original Research 30 December 2017 Pages: 770 - 779
An Innovative, Collaborative, and Strategic Approach to Proactively Evaluate and Update Drug Interactions Based on Prescribing Information of Newly Approved Medicinal Products Ariel PorcallaNella BarshteynMondira Bhattacharya Product Safety: Original Research 30 December 2017 Pages: 780 - 786
Impact of Expanded Access on FDA Regulatory Action and Product Labeling Jonathan P. JarowRichard Moscicki Regulatory Science: Original Research 30 December 2017 Pages: 787 - 789